OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operatio... OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs. 詳細を表示
NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer PR Newswire COCONUT GROVE, Fla., Dec. 10, 2024 Listing of OPKO Health-Branded...
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 36th Annual Healthcare Conference, being held...
NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo PR Newswire COCONUT GROVE, Fla., Nov. 18, 2024 OPKO Healthcare's Veterinary Care...
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results PR Newswire COCONUT GROVE, Fla., Nov. 14, 2024...
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today...
MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0499 | -3.11894493406 | 1.5999 | 1.65 | 1.53 | 4766877 | 1.59062585 | CS |
4 | -0.01 | -0.641025641026 | 1.56 | 1.7585 | 1.48 | 4744820 | 1.57585315 | CS |
12 | 0.08 | 5.44217687075 | 1.47 | 1.7585 | 1.37 | 3899026 | 1.5482837 | CS |
26 | 0.3 | 24 | 1.25 | 1.7585 | 1.19 | 3579991 | 1.50738451 | CS |
52 | -0.05 | -3.125 | 1.6 | 1.7585 | 0.8516 | 6600643 | 1.17439198 | CS |
156 | -2.83 | -64.6118721461 | 4.38 | 5.25 | 0.8516 | 4444055 | 1.75473624 | CS |
260 | 0.05 | 3.33333333333 | 1.5 | 6.47 | 0.8516 | 6303500 | 2.75301653 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約